GlassScriptPhysician profile
Donald K Mooney
NPI 1275508897
$147,617.01
in general payments reported to CMS, 2019-2025
40 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $27K · 2021: $24K · 2022: $28K · 2023: $1,499 · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Long Term Medical Supply Or Device Loan: $6,167 · Food and Beverage: $3,779 · Travel and Lodging: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,500.00 |
| Long Term Medical Supply Or Device Loan | $6,166.67 |
| Food and Beverage | $3,778.94 |
| Travel and Lodging | $2,814.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $124,500.00 | 2019-2024 | |
| Angiodynamics, INC. | $10,586.54 | 2023-2025 | Nanoknife, Nanoknife |
| Intuitive Surgical, INC. | $5,861.50 | 2019-2025 | |
| Teleflex LLC | $685.11 | 2021-2025 | Barrigel |
| Janssen Biotech, INC. | $623.30 | 2019-2023 | Erleada |
| Dendreon Pharmaceuticals LLC | $620.37 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $587.73 | 2019-2023 | Xtandi |
| Pfizer INC. | $445.85 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $404.38 | 2020-2023 | Prolaris, Myrisk |
| Boston Scientific Corporation | $306.65 | 2019-2023 | |
| Agiliti Surgical, INC. | $284.61 | 2025 | Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Myovant Sciences INC. | $270.00 | 2021-2022 | |
| Blue Earth Diagnostics | $260.36 | 2019-2023 | |
| Neotract INC. | $257.25 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $214.74 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $209.67 | 2019-2021 | |
| Abbvie INC. | $203.15 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $191.66 | 2023 | Orgovyx |
| Conmed Corporation | $161.70 | 2021-2022 | |
| Amgen INC. | $153.96 | 2019-2023 | Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $150.66 | 2019-2023 | |
| Profound Medical Corp. | $143.37 | 2025 | Tulsa-Pro |
| Verity Pharmaceuticals INC. | $70.36 | 2023 | Trelstar |
| Tolmar, INC. | $50.45 | 2023 | |
| Ferring Pharmaceuticals INC. | $50.07 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $40.70 | 2019 | |
| Urogen Pharma, INC. | $32.02 | 2020-2022 | |
| Davol INC. | $29.53 | 2020 | |
| Ambu INC. | $26.51 | 2025 | |
| Antares Pharma, INC. | $25.02 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $23.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.45 | 2021 | |
| Coloplast Corp | $20.52 | 2025 | |
| Janssen Scientific Affairs, LLC | $19.87 | 2019 | |
| Photocure INC | $18.46 | 2019 | |
| Axonics, INC. | $17.34 | 2022 | |
| Cure Medical LLC | $17.15 | 2020 | |
| Procept Biorobotics Corporation | $16.03 | 2021 | |
| Travere Therapeutics, INC. | $14.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$394,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.